- Scinai Immunotherapeutics Ltd. reported **revenues of $773 thousand** for the six months ended June 30, 2025, a significant increase from **$284 thousand** in the same period of 2024, reflecting continued growth in its CDMO business.  **[1611747_0001213900-25-083373_ea025545201ex99-1_scinai.htm:0]** 
- The company's net loss for the six months ended June 30, 2025, was **$4,134 thousand**, a decrease from **$4,481 thousand** in the prior year, primarily due to higher revenues and lower R&D expenses.  **[1611747_0001213900-25-083373_ea025545201ex99-1_scinai.htm:0]** 
- Research and development expenses for the six months ended June 30, 2025, amounted to **$1,237 thousand**, down from **$2,788 thousand** for the same period in 2024.  **[1611747_0001213900-25-083373_ea025545201ex99-1_scinai.htm:0]** 
- As of June 30, 2025, cash and cash equivalents totaled **$989 thousand**. Subsequently, in July and August 2025, the company raised an additional **$4.2 million** through its Standby Equity Purchase Agreement.  **[1611747_0001213900-25-083373_ea025545201ex99-1_scinai.htm:0]** 
- Scinai is advancing its anti-IL-17 NanoAb program and plans to apply for up to **€15 million** in grant financing under the EU STEP program, with a decision expected in Q1 2026.  **[1611747_0001213900-25-083373_ea025545201ex99-1_scinai.htm:0]**

Scinai Immunotherapeutics (SCNI)